Successful use of recombinant activated factor VII (eptacog alfa, Novoseven®) in a refractory bleeding during pediatric cardiac surgery: a case report

A 2-year-and-7-month-old boy underwent an emergent reconstruction surgery of the right ventricle-pulmonary artery (RV-PA) conduit. Although he was successfully weaned from cardiopulmonary bypass (CPB) after reconstruction of the RV-PA conduit, the bleeding continued despite the massive transfusion o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishihara, Mariko, Miyamoto, Yoshikazu, Taniguchi, Akihiro, Kinouchi, Keiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818693/
https://www.ncbi.nlm.nih.gov/pubmed/29497641
http://dx.doi.org/10.1186/s40981-015-0012-7
_version_ 1783301077989326848
author Ishihara, Mariko
Miyamoto, Yoshikazu
Taniguchi, Akihiro
Kinouchi, Keiko
author_facet Ishihara, Mariko
Miyamoto, Yoshikazu
Taniguchi, Akihiro
Kinouchi, Keiko
author_sort Ishihara, Mariko
collection PubMed
description A 2-year-and-7-month-old boy underwent an emergent reconstruction surgery of the right ventricle-pulmonary artery (RV-PA) conduit. Although he was successfully weaned from cardiopulmonary bypass (CPB) after reconstruction of the RV-PA conduit, the bleeding continued despite the massive transfusion of red blood cell (RBC), fresh frozen plasma (FFP), and platelets. Because of persistent bleeding and abnormal coagulation laboratory results, we administered the recombinant activated factor VII (rFVIIa), which was not approved for use in the treatment of post-CPB coagulopathy. After administration of rFVIIa, his coagulation data dramatically improved, the bleeding decreased, and the operation was able to be finished.
format Online
Article
Text
id pubmed-5818693
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-58186932018-02-27 Successful use of recombinant activated factor VII (eptacog alfa, Novoseven®) in a refractory bleeding during pediatric cardiac surgery: a case report Ishihara, Mariko Miyamoto, Yoshikazu Taniguchi, Akihiro Kinouchi, Keiko JA Clin Rep Case Report A 2-year-and-7-month-old boy underwent an emergent reconstruction surgery of the right ventricle-pulmonary artery (RV-PA) conduit. Although he was successfully weaned from cardiopulmonary bypass (CPB) after reconstruction of the RV-PA conduit, the bleeding continued despite the massive transfusion of red blood cell (RBC), fresh frozen plasma (FFP), and platelets. Because of persistent bleeding and abnormal coagulation laboratory results, we administered the recombinant activated factor VII (rFVIIa), which was not approved for use in the treatment of post-CPB coagulopathy. After administration of rFVIIa, his coagulation data dramatically improved, the bleeding decreased, and the operation was able to be finished. Springer Berlin Heidelberg 2015-11-30 2015 /pmc/articles/PMC5818693/ /pubmed/29497641 http://dx.doi.org/10.1186/s40981-015-0012-7 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Case Report
Ishihara, Mariko
Miyamoto, Yoshikazu
Taniguchi, Akihiro
Kinouchi, Keiko
Successful use of recombinant activated factor VII (eptacog alfa, Novoseven®) in a refractory bleeding during pediatric cardiac surgery: a case report
title Successful use of recombinant activated factor VII (eptacog alfa, Novoseven®) in a refractory bleeding during pediatric cardiac surgery: a case report
title_full Successful use of recombinant activated factor VII (eptacog alfa, Novoseven®) in a refractory bleeding during pediatric cardiac surgery: a case report
title_fullStr Successful use of recombinant activated factor VII (eptacog alfa, Novoseven®) in a refractory bleeding during pediatric cardiac surgery: a case report
title_full_unstemmed Successful use of recombinant activated factor VII (eptacog alfa, Novoseven®) in a refractory bleeding during pediatric cardiac surgery: a case report
title_short Successful use of recombinant activated factor VII (eptacog alfa, Novoseven®) in a refractory bleeding during pediatric cardiac surgery: a case report
title_sort successful use of recombinant activated factor vii (eptacog alfa, novoseven®) in a refractory bleeding during pediatric cardiac surgery: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818693/
https://www.ncbi.nlm.nih.gov/pubmed/29497641
http://dx.doi.org/10.1186/s40981-015-0012-7
work_keys_str_mv AT ishiharamariko successfuluseofrecombinantactivatedfactorviieptacogalfanovoseveninarefractorybleedingduringpediatriccardiacsurgeryacasereport
AT miyamotoyoshikazu successfuluseofrecombinantactivatedfactorviieptacogalfanovoseveninarefractorybleedingduringpediatriccardiacsurgeryacasereport
AT taniguchiakihiro successfuluseofrecombinantactivatedfactorviieptacogalfanovoseveninarefractorybleedingduringpediatriccardiacsurgeryacasereport
AT kinouchikeiko successfuluseofrecombinantactivatedfactorviieptacogalfanovoseveninarefractorybleedingduringpediatriccardiacsurgeryacasereport

Ejemplares similares